Fig. 2: Immunogenicity of A/Singapore/INFIMH-16-0019/2016 N2 and A/Michigan/45/2015 N1 rTET-NAs, LVNA and IIV preparations in naïve mice. | npj Vaccines

Fig. 2: Immunogenicity of A/Singapore/INFIMH-16-0019/2016 N2 and A/Michigan/45/2015 N1 rTET-NAs, LVNA and IIV preparations in naïve mice.

From: Boosting neuraminidase immunity in the presence of hemagglutinin with the next generation of influenza vaccines

Fig. 2

Female BALB/c mice (n = 8 per group) were immunized twice (intramuscularly) and terminally bled 2 weeks after second immunization (A). Sera were collected two weeks after booster vaccination; sera pools from two animals were created and in turn tested via ELLA to assess NAI antibody activity using reassortant H6N2 A/Singapore/INFIMH-16-0019/2016 (B) or H6N1 A/Michigan/45/2015 (C) viruses as sources of sialidase, respectively. º symbol represents IC50 NAI titers without AF03 addition and ■ represents groups with AF03 addition. The solid lines represent the average measurement, and the dashed lines indicate the starting serum dilution used for testing. *p < 0.05; **p < 0.01; ***p < 0.001 (the red text/symbols are comparisons vs adjuvanted PBS/control). p < 0.001 for all comparisons between adjuvant and non-adjuvanted vaccines at same dose level.

Back to article page